TP53 and pancreatic adenocarcinoma: 4). Moreover, UCP-2 expression has been associated with paclitaxel resistance of p53 wildtype lung cancer, CPT-11 resistance of colon cancer, and gemcitabine resistance of pancreatic adenocarcinoma, non-small cell lung adenocarcinoma, or bladder carcinoma. Accordingly, experimental targeting of UCPs has been demonstrated to sensitize tumor cells to chemotherapy in vitro. (for review see Ref. 4).